<DOC>
	<DOCNO>NCT01918267</DOCNO>
	<brief_summary>This non-interventional , observational , open-label multi-center follow-up study patient U-Act-Early trial ( ML22497 ) evaluate long-term efficacy safety start tight control treatment RoActemra/Actemra ( tocilizumab ) and/or methotrexate patient early disease follow treatment accord standard care routine clinical practice three year follow-up , independently treatment patient receiving .</brief_summary>
	<brief_title>U-Act-After : An Observational Study Long-Term Efficacy Tight Control RoActemra/Actemra ( Tocilizumab ) and/or Methotrexate Patients With Early Rheumatoid Arthritis Who Have Participated U-Act-Early Study ( ML22497 )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients must participate UActEarly trial ( ML22497 ) ; adult patient ( &gt; 20 year age ) rheumatoid arthritis . Patients must willing give write informed consent Patients participate UActEarly trial Patients dropouts UActEarly trial due withdrawal consent , lose followup serious protocol violator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>